Compounded Tirzepatide+L-Carnitine (CarniTide®)

Tirzepatide + L-Carnitine

Level A
Compounded Tirzepatide+L-Carnitine (CarniTide®)

Editor: Dr. Jobby John, PharmD, FACA

Peptide Ledger review boards: Medical Review Board (Dr. Jobby John, PharmD, FACA; Dr. Richard Harris, MD, PharmD, MBA; Dr. Tracy Neal, MD; Dr. John Thoppil, MD; Dr. Natalie Kash, MD; Dr. Rahil Roopani, MD)Pharmacist Review Committee (Rachel Kuretich, PharmD, PharmD; Daniel Alonso, PharmD, PharmD; Christina Gunter, PharmD, PharmD; Patrick Gurley, PharmD, MS, PharmD, MS; Gyu-Hee Min, PharmD, PharmD)

Reviewed November 13, 2025

References are being re-verified against PubMed and will return with review dates.

A
Strong Evidence
Multiple randomized controlled trials and systematic reviews

Multiple randomized controlled trials and systematic reviews

Compounded Tirzepatide+L-Carnitine (CarniTide®) is an advanced, multidimensional, compounded subcutaneous solution for intensive weight/metabolic management. It requires close clinical monitoring and programmatic support for best outcomes.

Tirzepatide stimulates both GLP-1 and GIP receptors, suppressing appetite, improving glycemic control, and preferentially reducing body fat.
L-carnitine is being studied for effects on mitochondrial fatty acid oxidation and cellular ATP production, fat loss, and preservation of lean mass during caloric restriction.

Tirzepatide achieves robust weight loss, significant glycemic improvement, and substantive fat mass reduction in clinical trials (SURPASS, SURMOUNT). Systematic reviews have studied L-carnitine's effects on fat oxidation, metabolic rate, and muscle mass with weight loss.
Common adverse effects: GI symptoms (nausea, vomiting, constipation, diarrhea), mild injection site irritation, fishy odor (from L-carnitine), appetite suppression.
Serious risks: pancreatitis, gallstones, hypersensitivity, and potential contraindication in patients with MEN2 or medullary thyroid cancer history (tirzepatide specific); close monitoring highly recommended.

CarniTide’s use is validated only in adult populations; not recommended in pediatric, pregnant, or lactating women. Dose modification and enhanced monitoring are required in renal, hepatic, or complex metabolic states.

⚠️ Important safety information above

Dosing considerations for clinicians

Dosing considerations are available to verified clinicians.

Sign in for clinician access

Available through Lake Hills Pharmacy

Available through Lake Hills Pharmacy for verified clinicians. Contact us for more information.

Sign in as a verified clinician to see formulations and dosing.

Contact us for more information

For Healthcare Providers

New to Lake Hills Pharmacy? Join our provider network. Lake Hills Pharmacy is preparing peptide programs as regulatory guidance on compounded peptides develops. Contact us for more information.

Contact us for more information

For Patients

Interested in Compounded Tirzepatide+L-Carnitine (CarniTide®)? Connect with our medical team to discuss if this therapy is right for you.

or call us directly:

Clinical View: Complete drug monograph with evidence-based protocols. Switch to General View for patient-friendly information.

Important Information About Compounded Medications

Compounded medications that use FDA-approved ingredients are prepared under the supervision of licensed pharmacists and physicians. These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.

Lake Hills Pharmacy | Licensed 503A Compounding Pharmacy | Professional Medical Oversight Required